Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.

Abstract

INTRODUCTION:

Myxoid/round cell liposarcoma is the second most common subtype of liposarcoma. Chemotherapy and radiotherapy have a limited efficacy for treating advanced myxoid/round cell liposarcoma, with relatively serious side effects.

CASE PRESENTATION:

We herein present a 68-year-old Chinese woman initially diagnosed with advanced multiple intra-abdominal and pelvic round cell liposarcoma.She refused to receive cytotoxic chemotherapy and received apatinib as the first-line therapy, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens. This patient was partially responsive to apatinib with a dose of 500 mg daily. No serious drug-related side effects were observed.

CONCLUSION:

Our findings indicate that some cases of liposarcoma may be responsive to antiangiogenic agent apatinib. Randomized clinical studies are needed to further confirm the efficacy and safety of apatinib in the clinical treatment of liposarcoma.

• Authors: Min Dong, Jingwang Bi, Xiaohong Liu, Baocheng Wang, Jun Wang
• Journal: Medicine (Medicine (Baltimore)) Vol. 95 Issue 31 Pg. e4368 (Aug 2016) ISSN: 1536-5964 [Electronic] United States
• PMID: 27495042 (Publication Type: Case Reports, Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Pyridines
• Vascular Endothelial Growth Factor A
• apatinib

Topics

• Abdominal Neoplasms (diagnosis, drug therapy)
• Biopsy, Needle
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Immunohistochemistry
• Liposarcoma (diagnosis, drug therapy)
• Neoplasm Invasiveness (pathology)
• Neoplasm Staging
• Positron Emission Tomography Computed Tomography (methods)
• Protein Kinase Inhibitors (administration & dosage)
• Pyridines (therapeutic use)
• Risk Assessment
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)